October 2020
M T W T F S S
 1234
567891011
12131415161718
19202122232425
262728293031  

The owner of mickeylieberman.com may receive compensation for recommendations made in reference to the products or services on this website.

This compensation may be in the form of money, services, or complimentary products and could exist without any action from a website visitor.

Should you purchase a product or service that was recommended by mickeylieberman.com, it is understood that some form of compensation might be made to the mickeylieberman.com owner.

For example, if you click on an affiliate link at mickeylieberman.com and then make a purchase of the recommended product or service, mickeylieberman.com owner may receive compensation.

This Compensation Disclosure has been provided for your protection and to fully disclose any relationship between mickeylieberman.com product or service recommendations and the owners of those products or services.

Special Procedures

Click on Any Topic

Bone Marrow Transplants

Organ Transplants

Stem Cells

——————————————–

Euthanasia

Physician Assisted Suicide

Medical Topics
  • Long-Term Data Back Anti-PD-1 in Advanced Non-Squamous NSCLC
    (MedPage Today) -- Long-term data from an early first-line trial of pembrolizumab (Keytruda) plus chemotherapy showed that more than half of patients with advanced non-squamous non-small cell lung cancer (NSCLC) remained alive at 3 years. In cohort...
  • Suze Orman's Schwannoma
    (MedPage Today) -- Financial advisor, author and former CNBC host Suze Orman has always stressed that it is a mistake for people to ignore their money problems. Now she wants you to know that "the most vital and stupid mistake I could ever make...
  • 'License' to Smoke After Negative Lung Screening?
    (MedPage Today) -- Some individuals appear to interpret a negative low-dose CT (LDCT) lung screening scan as a green light to resume smoking, a post hoc analysis of the National Lung Screening Trial (NLST) found. For example, highly nicotine dependent...
  • Hunting Resistance Mechanisms in RET-Fusion Lung Cancer
    (MedPage Today) -- As detected by circulating tumor DNA (ctDNA), acquired resistance to pralsetinib (Gavreto) in RET fusion-positive lung cancer was relatively uncommon, findings from the ARROW study suggested. In 42 non-small cell lung cancer...
  • Dual Checkpoint Blockade With Some Chemo Boosts OS in NSCLC
    (MedPage Today) -- A first-line immune checkpoint inhibitor combination of nivolumab (Opdivo) plus ipilimumab (Yervoy) improved survival in patients with advanced non-small cell lung cancer (NSCLC) when added to a limited course of chemotherapy...
Content Protected Using Blog Protector By: PcDrome.